Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522642 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL14448890 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL1999659 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL22401643 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL11031564 | 1.00 | HRH3 (0.57) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL1713933 | 0.98 | ALDH1A1 (0.54) | HRH3ALDH1A1MAPTHDAC1HDAC2 | |
| SCHEMBL5097451 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 | |
| SCHEMBL9227809 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 | |
| SCHEMBL2201281 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 | |
| SCHEMBL6709272 | 0.95 | HDAC1 (0.58) | HRH3ALDH1A1HDAC1HDAC2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112740018-B | Narrow absorbing polymer nanoparticles and related methods | 华盛顿大学 | 2025-06-17 | — | — | CN | disclosed |
| US-20220025111-A1 | NARROW ABSORPTION POLYMER NANOPARTICLES AND RELATED METHODS | UNIVERSITY OF WASHINGTON (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3853590-A1 | NARROW ABSORPTION POLYMER NANOPARTICLES AND RELATED METHODS | University of Washington (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020060937-A1 | NARROW ABSORPTION POLYMER NANOPARTICLES AND RELATED METHODS | UNIVERSITY OF WASHINGTON (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2018112649-A1 | AMIDINE SUBSTITUTED ANALOGUES AND USES THEREOF | VERLYX PHARMA INC. (CA) | 2018-06-28 | — | — | WO | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| EP-0137242-B1 | (SUBSTITUTED) PHENYL-ALIPHATIC-ISOXAZOLES USEFUL AS ANTIVIRAL AGENTS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-5002960-A | Viricides for combating picornaviruses | STERLING DRUG, INC. (US) | 1991-03-26 | — | — | US | disclosed |
| US-4939267-A | Viricides | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4857539-A | Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents | STERLING DRUG INC. (US) | 1989-08-15 | — | — | US | disclosed |
| US-4843087-A | OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES | STERLING DRUG INC. (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0207453-A2 | Heterocyclic substituted-phenoxyalkyl-isoxazoles and-furans, their preparation and use as antiviral agents | STERLING WINTHROP INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| EP-0137242-A2 | (Substituted) Phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof | STERLING WINTHROP INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| EP-0111345-A2 | Isoxazoles, useful as antiviral agents, and preparation thereof | STERLING DRUG INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4451476-A | Isoxazoles as antiviral agents | STERLING DRUG INC. (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | HRH3 2183/4885ALDH1A1 4854/4885MAPT 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.